Clinical trial TOTAL
A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance (TOTAL)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Lysarc |
| EudraCT Identifier | 2017-000409-19 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03496779 |
| Inclusion criteria | CD30 positive Peripheral T-cell Lymphoma/Ann Arbor stage I-IV/at least 1 measurable lesion >=1,5cm |
| Last update |